首页 > 抗体蛋白 > 抗体
Brilliant Violet 421™ anti-mouse NK-1.1 Anti
产品名称:
Brilliant Violet 421™ anti-mouse NK-1.1 Anti
产品类别:
抗体
产品编号:
108731
产品应用:
108731
[价格]
规格 价格 库存
125µL ¥ 2702 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
NK-1+ cells from mouse spleen and bone marrow
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

SB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤ 0.5 ?g per million cells in 100 ?l volume. For immunofluorescent staining using ?l sizes, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, complement-dependent cytotoxicity3, in vivo depletion4,5,9,10, mediation of in vitro redirected lysis6, blocking of NK cell function7, induction of proliferation8, immunohistochemical staining of frozen sections11, immunofluorescence microscopy11, and spatial biology (IBEX)16,17. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 108712).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
  2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
  3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
  4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
  5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
  6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
  8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
  9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
  10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
  11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
  12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
  13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
  14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
  16. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  17. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed
  2. Zhao Z, et al. 2021. Nat Commun. 12:4355. PubMed
  3. Wiesner DL, et al. 2020. Cell Host Microbe. 614:27. PubMed
  4. Machata S, et al. 2021. Front Immunol. 11:565869. PubMed
  5. Minutti CM, et al. 2019. Immunity. 50:645. PubMed
  6. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  7. Godbersen-Palmer C, et al. 2020. J Immunol. 204:2973. PubMed
  8. Li Q et al. 2018. Immunity. 48(2):258-270 . PubMed
  9. Bhattacherjee A, et al. 2019. Commun Biol. 2:450. PubMed
  10. Adams RCM, et al. 2019. Mediators Inflamm. 2019:9160941. PubMed
  11. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  12. Lin J, et al. 2017. Sci Rep. 7:41722. PubMed
  13. Garcia LR, et al. 2021. Nat Commun. 12:3364. PubMed
  14. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  15. Yang P, et al. 2022. Nat Commun. 13:5782. PubMed
  16. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  17. Gordon E, et al. 2015. Proc Natl Acad Sci U S A. 112: 13075 - 13080. PubMed
  18. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  19. Duan H, et al. 2021. J Clin Invest. 131:. PubMed
  20. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  21. Santecchia I, et al. 2019. PLoS Pathog. 15:e1007811. PubMed
  22. Hu M, et al. 2020. Cancer Immunol Res. 8:1150. PubMed
  23. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  24. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
  25. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  26. Collins PL et al. 2018. Cell. 176(1-2):348-360 . PubMed
  27. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
  28. Damgaard RB et al. 2016. Cell. 166(5):1215-1230 . PubMed
  29. Rasid O, et al. 2020. Cell Reports. 29(12):3933-3945.e3.. PubMed
  30. Hakim R, et al. 2021. J Neurosci. 41:8441. PubMed
  31. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  32. Dhayade S, et al. 2020. Nutrients. 12:. PubMed
  33. Liu H et al. 2017. Cell host & microbe. 22(5):653-666 . PubMed
  34. Jolly A, et al. 2022. Cell Rep Methods. 2:100315. PubMed
  35. Boulch M, et al. 2021. Sci Immunol. 6:. PubMed
  36. Tomita T, et al. 2021. Nat Commun. 12:3655. PubMed
  37. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  38. Dyer DP et al. 2019. Immunity. 50(2):378-389 . PubMed
  39. Patil ND, et al. 2022. Front Immunol. 13:818015. PubMed
  40. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
RRID
AB_10895916 (BioLegend Cat. No. 108731) AB_2562561 (BioLegend Cat. No. 108741) AB_2562218 (BioLegend Cat. No. 108732)

Antigen Details

Structure
NKR-P1 gene family
Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function
NK cell activation, IFN-γ production, cytotoxic granule release
Cell Type
NK cells, NKT cells
Biology Area
Immunology, Innate Immunity
Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID
17059 View all products for this Gene ID
UniProt
View information about NK-1.1 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线